ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that Australia’s Therapeutic Goods Administration (TGA) has approved Jetrea (ocriplasmin) for the treatment of adults with vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.

ThromboGenics’ partner Alcon, which is commercializing Jetrea outside the US, will be responsible for the launch of the drug in Australia.

For more details, go to: http://www.thrombogenics.com/content/thrombogenics’-jetrea®-gains-approval-australia